Omadacycline
|
|
|
- CAS-Nr.
- 389139-89-3
- Englisch Name:
- Omadacycline
- Synonyma:
- OMadacycline;AMadacycline;PTK-796;PTK 0796;Omadacycline-D9;2H9]-Omadacycline;Omadacycline (PTK 0796;Amadacycline，Omadacycline，PTK 0796;OMADACYCLINE; PTK 0796; PTK-0796; PTK0796; AMADACYCLINE;(4S,4aS,5aR,12aS)-4,7-Bis(dimethylamino)-3,10,12,12a-tetrahydroxy-9-((neopentylamino)methyl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
- CBNumber:
- CB42627315
- Summenformel:
- C29H40N4O7
- Molgewicht:
- 556.65
- MOL-Datei:
- 389139-89-3.mol
|
Omadacycline Eigenschaften
- Siedepunkt:
- 837.6±65.0 °C(Predicted)
- Dichte
- 1.39±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- Löslichkeit
- DMSO:1.0(Max Conc. mg/mL);1.8(Max Conc. mM)
- Aggregatzustand
- A crystalline solid
- pka
- 4.50±1.00(Predicted)
- Stabilität:
- Hygroscopic
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
 
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H361 |
Kann vermutlich die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. |
Reproduktionstoxizität |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P281 |
Vorgeschriebene persönliche Schutzausrüstung verwenden. |
| P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
| P330 |
Mund ausspülen. |
| P405 |
Unter Verschluss aufbewahren. |
| P501 |
Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Omadacycline Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Omadacycline, the drug that US FDA approved for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It is not susceptible to common tetracycline-resistancemechanisms, and has demonstrated efficacy against a broad spectrum of pathogens including resistant isolates, which are increasing in prevalence and complexity.
Verwenden
Omadacycline is a potent an demonstrates efficacy against both Bacillus anthracis and Yersinia pestis; Also, it is a novel aminomethylcycline antibiotic in clinical development for community-acquired bacterial pneumonia (CABP).
Pharmakologie
Omadacycline has shown clinical efficacy in anaerobic acute bacterial skin and skin structure infections (ABSSSI) and in animal models of intra-abdominal anaerobic infections.The in vitro activity of Omadacycline against clinically relevant anaerobes was similar to that of tigecycline, with MIC90 values of 1 to 8 g/ml against Bacteroides spp, 0.5 g/ml against Clostridium difficile, Prevotella spp., and Porphyromonas asaccharolytica,1 g/ml against Peptostreptococcus spp, and 16 g/ml against Clostridium perfringens.
Nebenwirkungen
OMadacycline may cause serious adverse reactions including hypersensitivity reactions, tooth discoloration,Clostridioides difficile-associated diarrhea, and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy.Common adverse reactions include nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation.Mild to moderate nausea and vomiting were the most frequent treatment-emergent adverse events in omadacycline (111 [30%] of 368 and 62 [17%] of 368, respectively) groups.
Omadacycline Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Omadacycline Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 76)Lieferanten
389139-89-3()Verwandte Suche:
[4S-(4α,4aα,5aα,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacen-2-carboxamidmonohydrochlorid
Fosfomycin
oxytetracyclin
Tetracyclin
- PTK 0796
- PTK-796
- OMADACYCLINE; PTK 0796; PTK-0796; PTK0796; AMADACYCLINE
- 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-
- Omadacycline-D9
- AMadacycline
- OMadacycline
- Amadacycline，Omadacycline，PTK 0796
- 2H9]-Omadacycline
- Omadacycline (PTK 0796
- spectrum,antibacterial,pathogens,Omadacycline,synthesis,Inhibitor,urinary,community-acquired,PTK-0796,skin-structure,anaerobic,acute,protein,pneumonia,tetracycline,inhibit,skin,Gram-negative,atypical,Antibiotic,Gram-positive,tract,PTK0796,broad,Bacterial,infections,agent
- (4S,4aS,5aR,12aS)-4,7-Bis(dimethylamino)-3,10,12,12a-tetrahydroxy-9-((neopentylamino)methyl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
- 389139-89-3
- C29H40N4O7
